One To Watch

Kailera Therapeutics

A clinical-stage biopharmaceutical company focused on obesity and weight management, with a pipeline of injectable and oral GLP-1–based therapies spanning multiple mechanisms and dosing formats.

Headquarters and Global Presence

Kailera operates from U.S. hubs in Massachusetts and California and is advancing global development programs for obesity. The company’s lead assets were licensed from Jiangsu Hengrui Pharmaceuticals and have clinical data packages generated in China alongside Kailera-led global development.

Founding and History

Kailera launched in October 2024 with a $400 million Series A financing and exclusive rights outside Greater China to a portfolio of four metabolic disease assets licensed from Hengrui (May 2024). In October 2025, the company announced a $600 million Series B to fund global pivotal development of its lead program. In January 2026, Kailera announced first participant randomization in its global Phase III KaiNETIC program.

Therapy Areas and Focus

Kailera is focused on clinical obesity and chronic weight management, including adults living with obesity or overweight with comorbidities. Development is positioned to address a range of patient preferences and treatment pathways through both injectable and oral options.

Technology Platforms and Modalities

Kailera’s portfolio centers on incretin-based pharmacology across:

Dual GLP-1/GIP receptor agonism (peptide, injectable and oral formulations)
GLP-1 receptor agonism (oral small-molecule approach)
Triple agonism targeting GLP-1/GIP/glucagon receptors (injectable peptide)

Programs and Clinical Pipeline

Ribupatide franchise (GLP-1/GIP dual agonist)

Ribupatide, once-weekly injectable (KAI-9531; developed in China as HRS9531): Phase III global program (KaiNETIC)
Oral ribupatide (KAI-9531-T; HRS9531 tablet): Phase II positive topline data reported in China; Kailera has stated plans for a global Phase II trial in 2026

Other clinical-stage obesity assets

KAI-7535: once-daily oral small-molecule GLP-1 receptor agonist; clinical-stage, with prior Phase II data generated in China referenced by the company
KAI-4729: once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist; clinical-stage development for obesity

Key Personnel

Ron Renaud, President and Chief Executive Officer
Scott Wasserman, MD, Chief Medical Officer
Paul Burgess, Chief Operating Officer and Chief Business Officer
Doug Pagán, Chief Financial Officer (appointed January 5, 2026)

Strategic Partnerships

Kailera’s core partnering relationship is with Jiangsu Hengrui Pharmaceuticals, which originated the licensed obesity portfolio and continues to progress ribupatide programs in China (including regulatory filings and local late-stage development). The structure provides Kailera with development and commercialization rights outside Greater China and access to clinical datasets generated in China.

FAQ Section

Kailera develops obesity medicines built around GLP-1–based mechanisms, using both peptide and small-molecule modalities and multiple routes of administration. The strategy is to offer differentiated efficacy, tolerability, and convenience profiles within the incretin class.

Kailera is focused on obesity and long-term weight management, including patients with obesity and those who are overweight with comorbidities.

The disclosed pipeline includes four clinical-stage candidates: the ribupatide franchise (KAI-9531 injectable and KAI-9531-T oral), KAI-7535 (oral small-molecule GLP-1 receptor agonist), and KAI-4729 (injectable GLP-1/GIP/glucagon tri-agonist).

February 10, 2026: Kailera and Hengrui reported positive topline Phase II data from a China trial of oral ribupatide and stated next-step plans (Hengrui Phase III in China; Kailera global Phase II in 2026).
January 12, 2026: Kailera announced first participants randomized in the KaiNETIC global Phase III program for injectable ribupatide (KAI-9531).
January 5, 2026: Kailera appointed Doug Pagán as Chief Financial Officer.
October 14, 2025: Kailera announced a $600 million Series B financing and described End-of-Phase II FDA meetings supporting Phase III plans for KAI-9531.
October 1, 2024: Kailera launched with a $400 million Series A and disclosed the licensed portfolio from Hengrui.

Ribupatide is a GLP-1/GIP receptor dual agonist being advanced in two formulations: a once-weekly injectable product in global Phase III (KaiNETIC) and a once-daily oral tablet with Phase II topline data reported in China. Kailera’s public strategy is to develop both injectable and oral options under the same franchise.

Key disclosed regulatory and execution milestones include continued Phase III conduct for injectable ribupatide and initiation of a global Phase II trial for oral ribupatide in 2026. The company has also stated it completed End-of-Phase II meetings with the FDA supporting its Phase III design.

Kailera’s differentiation claim is portfolio-based: multiple clinical-stage assets across peptide and oral formats, including a dual agonist franchise and additional mechanisms (oral small-molecule GLP-1 and a tri-agonist). The practical proof points to watch are head-to-head–relevant Phase III outcomes, discontinuation rates, and durability of weight loss at maintenance doses.

Want to Update your Company's Profile?